Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

By sjmartinez • July 7, 2023

Zhang J, McAndrew NP, Wang X, Du Y, DiCarlo B, Wang M, Chen K, Yu W, Hu X. Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor. Breast Cancer Res. 2023 Jul 6;25(1):81. doi: 10.1186/s13058-023-01679-4. PMID: 37415239.

Tags: blood–brain barrier, breast cancer, Central nervous system metastases, Hematology/Oncology, HER2, Publications, Tyrosine kinase inhibitor

Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation

Saco JD, Karin D, Patten JJ, Bachl S, Ching C, Kale N, Fan Y, Medina E, Naser Al Deen N, Champhekar A, Kaelin WG, Schulman[...]

Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance

Nishimura RN, Gera JF. Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance. Int J Mol Sci. 2026 Sep[...]

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

Tsimberidou AM, Cabanski CR, Drakaki A, Khalil DN, Siddiqui BA, Basu S, Okrah K, Da Silva DM, Gautam S, Alayli FA, Schachter M, Fairchild J,[...]